Genetic risk, incident colorectal cancer, and the benefits of adhering to a healthy lifestyle: A prospective study using data from UK Biobank and FinnGen

E. Wu1,2†, Jun-Tao Ni3†, Xin Chen2, Zhao-Hui Zhu2, Hong-Quan Xu1,4, Lin Tao1,4* and Tian Xie1,4*

1School of Pharmacy, Hangzhou Normal University, Hangzhou, China, 2School of Public Health, Hangzhou Normal University, Zhejiang, China, 3Scientific Research Department, Women’s Hospital School of Medicine Zhejiang University, Hangzhou, China, 4Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, China

Background: Genetic factors increase the individual risk of colorectal cancer (CRC); however, the extent to which a healthy lifestyle can offset increased genetic risk is unknown. This study investigated whether a healthy lifestyle is associated with lower CRC risk, regardless of genetic risk.

Methods: We recruited 390,365 participants without cancer at baseline (2006–2010) from the UK Biobank. The primary outcome was CRC incidence. A healthy lifestyle score constructed using 16 factors of six dimensions (smoking, drinking, body mass index, diet, exercise, and sleep) was categorized into three risk categories: favorable, intermediate, and unfavorable. To calculate the polygenic risk scores (PRSs) of UK Biobank participants, we extracted 454,678 single nucleotide polymorphisms (SNPs) from the UK Biobank and FinnGen Biobank after quality control. Cox proportional hazards regression was performed to evaluate the associations and was expressed as hazard ratios (HRs) with 95% confidence intervals (CIs).

Results: During a median follow-up of 10.90 years, 4,090 new CRC cases were reported in the UK Biobank. The “best-fit” PRSs were constructed using 59 SNPs based on the UK Biobank cohort and FinnGen genome-wide association study summary data ($R^2 = 0.23$%) and were divided into low (lowest quintile), intermediate (including second–fourth quintile), and high (highest quintile) genetic risk categories. The multivariate-adjusted Cox model revealed that participants with favorable lifestyles had HRs of 0.66 (95% CI = 0.60–0.72) for developing CRC vs. those with unfavorable lifestyles; low genetic risk was associated with a decreased risk of CRC (HR = 0.67, 95% CI = 0.61–0.74) compared with those with high genetic risk. The HRs for low genetic risk participants with favorable lifestyles were 0.44 (95% CI =0.36–0.55) vs. participants with high genetic risk and unfavorable lifestyles. Among the
participants with low, intermediate, or high genetic risk, the HRs of favorable vs. unfavorable lifestyles were 0.74, 0.64, and 0.72 (all \( p < 0.05 \)).

**Conclusions:** Low genetic risk and a favorable lifestyle were significantly associated with a decreased risk of CRC. A favorable lifestyle was associated with a lower CRC risk, regardless of genetic risk.

**KEYWORDS**
colorectal cancer, polygenic risk scores, lifestyle factors, epidemiology, prevention

---

**Introduction**

Colorectal cancer (CRC) is the third most common cancer and the fourth leading cause of cancer-related death worldwide (1). As a complex disease, CRC is determined by the interplay between genetic and lifestyle factors (2). Genome-wide association studies (GWASs) with large sample sizes have revealed that hundreds of independent loci are associated with CRC risk (3–10). Although each genetic variant contributes little to CRC, when aggregated into a polygenic risk score (PRS), these associated alleles can provide an overall measure of genetic susceptibility to certain diseases. Therefore, research on the relationship between CRC risk and PRS has attracted widespread attention.

The American Cancer Society (ACS) has emphasized the critical role of lifestyle management in CRC prevention (11). However, previous studies on CRC prevention have concentrated on limited factors, such as smoking, alcohol consumption, exercise, sedentary behavior, and intake of fruits and vegetables, while emerging factors, such as sleep and intake of whole and refined grains, have been excluded from the lifestyle scores. Owing to the increasing number of people with sleep disorders (12, 13), and sleep disorders have been shown to increase the risk of CRC (14–16). Incorporating emerging factors such as sleep into lifestyle scores to illustrate the benefits of a healthy lifestyle in CRC prevention should be addressed.

Therefore, this study aimed to evaluate the genetic risk of CRC among UK Biobank participants (created PRS based on GWAS summary data from the FinnGen biobank) and to determine whether adherence to a favorable lifestyle (including emerging factors such as sleep) is associated with a lower risk of CRC, regardless of genetic risk.

**Methods**

**Study population**

We obtained data from the UK Biobank and FinnGen cohort in this study. A detailed introduction to the UK Biobank has been provided elsewhere (https://www.ukbiobank.ac.uk/). Briefly, the UK Biobank collected and stored blood samples of approximately half a million volunteers from 2006 to 2010 and continually followed up their health and medical information. We extracted 502,414 participants from the UK Biobank. Exclusion criteria were (1) participants with missing values or without genotype data (\( n = 37,959 \)); (2) nonwhite ethnic background (\( n = 27,385 \)); and (3) with cancer at baseline, were diagnosed with CRC or died within the first 2 years of follow-up, or were lost to follow-up (\( n = 40,551 \)). The present analyses were restricted to individuals from white ethnic backgrounds with available genetic and lifestyle information. After exclusion, 396,519 potentially eligible participants remained for further analyses (Supplementary Figure S1).

The CRC GWAS summary statistics in this study were obtained from the FinnGen Biobank and included 215,770 controls and 3,022 CRC cases (https://finngen.gitbook.io/documentation/). FinnGen data are openly available online. The need for ethical approval and consent to participate was waived, for they have been obtained from the original studies. The UK Biobank obtained ethical approval from the North West Multicenter Research Ethics Committee (reference no. 16/NW/0274). All the UK Biobank participants signed an informed consent form. This study was approved by the UK Biobank (no. 78563).

---

**Abbreviations:** CRC, colorectal cancer; SNP, single nucleotide polymorphism; PRS, polygenic risk scores; HR, hazard ratio; CI, confidence interval; GWAS, genome-wide association study; GPC, genetic principal component; MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium; SD, standard deviation; BMI, body mass index; TDI, Townsend deprivation index.
Polygenic risk score

Polygenic risk score calculation requires separate base (GWAS summary statistics) and target data (individual-level genotype–phenotype data), as described previously (17, 18). For the base data, we used the FinnGen biobank GWAS summary data; for the target data, we used 396,519 individuals from the UK Biobank, which contains individual-level genotypes.

Both the base and target data require quality control. First, we filtered the base data of the FinnGen cohort. From a total of 16,380,465 single nucleotide polymorphisms (SNPs), we excluded 7,279,657 SNPs due to a minor allele frequency (MAF)<1% (18). Second, regarding the target data of 396,519 UK Biobank participants, we selected version 2 of the non-imputed genotype data (continued to be correct and current) for UK Biobank, which contains individual-level genotypes.

Exclusion criteria were as follows (19): (1) missing ratio for SNPs must be<0.2, and that of male individuals must be>0.8). The chromosome homozygosity estimate of female individuals was obtained at baseline by using a validated touchscreen questionnaire. Participants accumulated 1 point once in accordance with each of following six healthy lifestyle patterns based on ACS guidelines or national recommendations (Supplementary Table S1): 1) never smoked (24); 2) moderate alcohol consumption [women ≤ 14 g/day or men ≤ 28 g/day (25)]; 3) regular exercise (moderate physical activities ≥ 150 min/week, or ≥ 5 days/week, or vigorous exercise ≥ 75 min/week, or ≥ once a week, or an equivalent combination (26, 27); 4) healthy diet (individuals incorporating at least three of the following dietary behaviors: fruits ≥ 3 servings/day, vegetables ≥ 3 servings/day, fish ≥ twice a week, processed meats ≤ once a week, red meats ≤ twice a week, whole grains ≥ 3 servings/day, refined grains ≤ 1 serving/day (28); 5) sleeping well (individuals having at least three of the following healthy sleep behaviors: sleep duration, 7–8 h/day, chronotype indicated as morning person, never or sometimes insomnia, no snoring, never or sometimes daytime dozing (29); and 6) normal weight, 18.5 kg/m² ≤ body mass index (BMI)<25.0 kg/m² is considered healthy weight (30). The total healthy lifestyle score ranges from 0 to 6, and the higher the score, the higher the tendency for a healthy lifestyle. Healthy lifestyle scores were categorized into three groups: unfavorable (scored 0–2 points), intermediate (scored 3–4 points), and favorable (scored 5-6 points).

Covariates

Covariate information was obtained at baseline, including the age when attending the assessment center; sex (female, male); ethnic background (British, Irish, any other white background); socioeconomic status as measured using the Townsend deprivation index (TDI), which combining information on non-homeownership, household overcrowding, non-car ownership, and unemployment at recruitment (31); and education (higher: college or university; middle: A levels/AS levels or equivalent, O levels/GCSEs or equivalent; lower: CSEs or equivalent, NVQ, HND, HNC, or equivalent; vocational: professional qualifications, e.g., nursing, teaching; other).

Ascertainment of CRC outcome

The primary outcome was the first incident CRC diagnosis or CRC first documented on the death certificates. Death information from the UK Biobank was obtained from the “death registry,” which is linked to the National Health Service
(NHS) Central Register (Scotland participants) and NHS Digital Center (England/Wales participants) (32). Participants who died of CRC were recorded by the 10th revision of the International Classification of Diseases (ICD-10) (coding: C18, C19, and C20). The date of the “death registry” was updated to 31 October 2021 (for Scotland participants) or 30 September 2021 (for England/Wales participants).

The details of the first incident CRC diagnosis were obtained from the “cancer registry,” which is linked to the Information Services Division of the NHS Scotland (Scotland participants) and the Medical Research Information Service of the NHS (England/Wales participants) (33). CRC incidence was diagnosed using ICD-10 (C18, C19, and C20), the ICD-9 (153, 1540, and 1541), and self-reported cancer (1020, 1022, and 1023). The follow-up person-years of each participant were calculated from the baseline survey time to either the date of CRC outcome, death for any reason, 31 October 2015 (for Scotland participants), or 29 February 2020 (for England/Wales participants), whichever occurred first.

Statistical analysis

The baseline characteristics of each participant are presented by CRC status as frequencies (percentages) for categorical variables and median [(interquartile range) (IQR)] for non-normally distributed continuous variables. Pearson’s $\chi^2$ test was used to analyze unordered categorical variables, and the Wilcoxon rank test was used to analyze grade variables or non-normally distributed continuous variables. The reverse Kaplan–Meier method was used to calculate the median follow-up time.

Cox proportional hazards regression was used to evaluate the associations of genetic, lifestyle, and combined genetic–lifestyle factors with the risk of CRC; it was adjusted for potential confounding factors, and the results were expressed as adjusted hazard ratios (HRs) with 95% confidence intervals (CIs). Model 1 was adjusted for age (years), sex (male and female), education (higher, middle, lower, vocational, and other), Townsend deprivation index, and the first 10 genetic principal components (GPCs) at recruitment; Model 2 was additionally adjusted for healthy lifestyle scores (0–6), and Model 2b was additionally adjusted for the PRS based on Model 1. The proportionality of hazards assumption was examined using the Schoenfeld residuals; no evidence of non-proportionality was observed. Multiplicative interactions were calculated using Cox regression adjusted for Model 1. A restricted cubic spline (RCS) using three knots was used to examine dose–response associations. Additionally, absolute risks (ARs) were calculated using the CRC incidence in each risk group (34, 35).

Sensitivity analysis was conducted to examine the robustness of the findings. First, stratified analyses were conducted according to age at baseline, sex, socioeconomic status, and education. Second, weighted lifestyle scores were created and classified into three groups: unfavorable, intermediate, and favorable. Statistical analyses were performed using SAS version 9.1 (SAS Institute, Cary, NC, USA), and graphs were plotted using R [version 4.1.3; R Core Team (2022); Vienna, Austria]. All $p$-values were two-sided, and a $p$-value $<0.05$ was considered statistically significant.

Results

The baseline characteristics of the 390,365 participants who were followed up for a median of 10.90 years (follow-up 4,135,798 total person-years) are presented by CRC status in Table 1. There were 4,090 cases of CRC. Participants without CRC were younger, more likely to be female, had a healthy diet, had normal weight, and never smoked ($p < 0.05$) (Supplementary Table S2). Among 454,678 SNPs for PRS calculation, we found that a $p$-value $< 5 \times 10^{-8}$ threshold, containing 59 SNPs, generated a “best-fit” PRS ($R^2 = 0.23\%$) (Supplementary Figure S2). The “best-fit” PRS and healthy lifestyle score (from 0 to 6 points) were all in accordance with a normal distribution (Supplementary Table S3). The dose–response relationship suggested a positive association between PRS and CRC risk (Supplementary Figure S4). The PRS was then categorized into three genetic risk groups: low (lowest quintile), intermediate (including second–fourth quintile), and high (highest quintile). Notably, genetic risk categories were not associated with any lifestyle factors except for smoking status and exercise (Supplementary Table S3).

The risk of CRC decreased monotonically across the healthy lifestyle groups (Table 2). Participants with a favorable lifestyle had an HR of 0.66 (95% CI = 0.60–0.72), and those with an intermediate lifestyle had an HR of 0.77 (95% CI = 0.72–0.83) for developing CRC vs. those with an unfavorable lifestyle in Model 1. The results remained significant after additional adjustment for PRS in Model 2. The HRs for favorable and intermediate lifestyles were 0.66 (95% CI = 0.60–0.72) and 0.78 (95% CI = 0.72–0.83), respectively. A similar pattern of effects was observed when healthy lifestyle scores were used as continuous variables (Supplementary Table S4).

A decreased monotonically gradient risk of CRC was also observed across low genetic risk groups (Table 3). Participants with low genetic risk had HRs of 0.67 (95% CI = 0.61–0.74), and intermediate genetic risk participants had HRs of 0.78 (95% CI = 0.73–0.84) for developing CRC vs. high genetic risk participants. The AR for CRC was 1.3% in the high-risk genetic group and 0.9% in the low-risk genetic group. In addition, the higher PRS quintiles were also associated with a monotonically increased risk of CRC compared with the lowest quintile (Supplementary Table S5).

To explore the impact of lifestyle on CRC risk according to different genetic risk categories, we stratified lifestyles by genetic risk category using unfavorable lifestyles as the reference group.
and found that favorable lifestyles were associated with a lower risk of CRC in any genetic risk group (Table 4). In the low genetic risk category, participants with a favorable lifestyle had an HR of 0.74 (95% CI = 0.51–0.81) for developing CRC vs. participants with an unfavorable lifestyle. The HRs of favorable lifestyles vs. unfavorable lifestyles among participants in intermediate and high genetic risk category were 0.64 (95% CI = 0.56–0.72) and 0.72 (95% CI = 0.60–0.87), respectively.

We further combined the genetic and lifestyle categories to explore the joint effects of genetic–lifestyle on CRC risk. As shown in Figure 1, participants with low genetic risk and favorable lifestyles had an HR of 0.44 (95% CI = 0.36–0.55) for developing CRC vs. participants with high genetic risk and unfavorable lifestyles. The HRs for low genetic risk participants with unfavorable lifestyles were 0.69 (95% CI = 0.58–0.82) vs. participants with high genetic risk and unfavorable lifestyles.

The sensitivity analysis indicated that the results were robust. First, low genetic risk combined with a healthy lifestyle has been observed to be associated with lower CRC risk when stratified by age, sex, socioeconomic status, and education (Supplementary Tables S6–S9). Second, the results did not

| TABLE 1 Baseline characteristics of the study participants by CRC status. |
|---------------------------------------------------------------|
| Characteristic | Incident CRC | p-value |
|----------------|--------------|---------|
| No (n = 386275) | Yes (n = 4090) |         |
| Age, median (IQR)* | 57 (50,63) | 62 (57,66) | <0.001 |
| Sex* |  |  |  |
| Female | 206,991 (53.6) | 1,739 (42.5) |  |
| Male | 179,284 (46.4) | 2,351 (57.5) |  |
| TDI* |  |  |  |
| 1 (least deprived) | 77,246 (20.0) | 851 (20.8) | 0.392 |
| 2–4 (intermediate deprived) | 231,783 (60.0) | 2,441 (59.7) |  |
| 5 (most deprived) | 77,246 (20.0) | 798 (19.5) |  |
| Education* |  |  | 0.001 |
| Higher | 127,986 (33.1) | 1,287 (30.5) |  |
| Middle | 129,664 (33.6) | 1,326 (32.4) |  |
| Lower | 46,887 (12.1) | 497 (12.2) |  |
| Vocational | 19,675 (5.1) | 224 (5.5) |  |
| Others | 62,063 (16.1) | 796 (19.5) |  |
| Healthy lifestyle factorsb,c |  |  |  |
| Healthy diet | 194,537 (50.4) | 1,985 (48.5) | 0.020 |
| Normal weight | 127,880 (33.1) | 1,079 (26.4) | <0.001 |
| Never smoked | 211,193 (54.7) | 1,879 (45.9) | <0.001 |
| Regular exercise | 284,657 (73.8) | 2,919 (71.4) | 0.001 |
| Sleep well | 234,927 (60.8) | 2,350 (57.5) | <0.001 |
| Moderate drinking | 279,395 (72.3) | 2,797 (68.4) | <0.001 |
| No. of healthy lifestyle scoresa |  |  | <0.001 |
| 0 | 4,225 (1.1) | 58 (1.4) |  |
| 1 | 25,326 (6.6) | 381 (9.3) |  |
| 2 | 64,567 (16.7) | 860 (21.0) |  |
| 3 | 100,695 (26.1) | 1,131 (27.7) |  |
| 4 | 103,037 (26.7) | 946 (23.1) |  |
| 5 | 66,654 (17.3) | 553 (13.5) |  |
| 6 | 21,771 (5.6) | 161 (3.9) |  |
| Genetic risk categorya |  |  | <0.001 |
| Low | 77,382 (20.0) | 687 (16.8) |  |
| Intermediate | 231,837 (60.0) | 2,386 (58.3) |  |
| High | 77,056 (19.9) | 1,017 (24.9) |  |

*The Wilcoxon rank test.

bPearson’s χ² test.

cBinary variable, showing one of the options.

TDI, Townsend deprivation index; due to the rounding off, the column percentages for each item may not be 100.
change when using the weighted lifestyle scores (Supplementary Figures S5, S6).

**Discussion**

This study presented the quantitative effects of genetic risk, lifestyle, and their joint effects on CRC risk using data from the UK Biobank and FinnGen. The results indicated that the high genetic risk was significantly correlated with an increased CRC risk. If individuals were at high genetic risk for CRC, the susceptibility of CRC may be enhanced but may also be modified through a healthy lifestyle, namely, as a result of their combined effects. Notably, adherence to a favorable lifestyle was correlated with a lower CRC risk, regardless of the genetic risk category.

Numerous studies have reported that decreased CRC risk is related to a healthy lifestyle, which is consistent with the results of this study (36–38). For instance, a Danish cohort study involving 55,487 participants constructed a lifestyle score for factors such as smoking, exercise, drinking, waist circumference, and diet and found that a healthy lifestyle was associated with reduced CRC risk (RR = 0.89) (39). Compared with past studies, our research scale was an order of magnitude larger, and genetic risk was considered. We selected 59 SNPs from 454,678 SNPs to construct the “best-fit” PRS, which can effectively evaluate the genetic susceptibility of CRC and help save costs. Although individuals may think that they are powerless against their CRC genetic susceptibility, our research shows that favorable lifestyles can still significantly lower the risk of CRC, regardless of genetic background. Within any genetic risk background, adherence to a favorable lifestyle may modify CRC risk and, to a certain extent, help to prevent CRC.

In recent years, studies on the genetic and lifestyle risks of CRC have begun. A recent study of 346,297 UK Biobank participants constructed PRS and a healthy lifestyle score including eight lifestyle factors (BMI, waist-to-hip ratio, exercise, sedentary time, intake of processed meat, red meat, vegetables, and fruits) and found that the PRS and healthy lifestyle had a significant additive interaction (p < 0.05) (40). However, the base data (containing 95 SNPs) used in that study were derived from two published articles, partially involving East Asians and African Americans (35, 41), and the lifestyle factors included in the analysis were not comprehensive enough. In our study, we used the entire FinnGen cohort (containing 16,380,465 SNPs) as the base data; the Finnish and UK populations are genetically closer compared to the UK population and East Asians and African Americans, and the SNPs selected to construct the PRS are also different. In addition, we included sleep duration; sleep chronotype; insomnia; snoring; daytime dozing; and intake of fish, whole grains, and refined grains in the construction of a healthy lifestyle score. Our study provides evidence of a healthy lifestyle for lower CRC risk, regardless of genetic background. Our findings are consistent with a case–control analysis using 7,558 German participants, which investigated the

**TABLE 2** Risk of CRC according to lifestyle category.

| Model | Lifestyle category | p-value for trend |
|-------|--------------------|-------------------|
|       | Unfavorable (n = 95,417) | Intermediate (n = 205,809) | Favorable (n = 89,139) |
| No. of CRC/person-years | 1,299/1,003,622 | 2,077/2,182,758 | 714/949,418 |
| Absolute risk | 1.4% | 1.0% | 0.8% |
| HR (95% CI) | 1.00 (ref) | 0.77 (0.72–0.83) | 0.66 (0.60–0.72) | <0.001 |
| HR (95% CI) | 1.00 (ref) | 0.78 (0.72–0.83) | 0.66 (0.60–0.72) | <0.001 |

CRC, colorectal cancer; HR, hazard ratio; CI, confidence interval.

*aModel 1, Cox proportional hazards regression adjusted for age, sex, education, Townsend deprivation index, and first 10 genetic principal components.

*bModel 2, Cox proportional hazards regression adjusted for Model 1 and polygenic risk scores.

p-value for trend was modeling the lifestyle categories as a continuous variable.

**TABLE 3** Risk of CRC according to genetic risk.

| Model | Genetic category | p-value for trend |
|-------|------------------|-------------------|
|       | High (n = 78,073) | Intermediate (n = 234,223) | Low (n = 78,069) |
| No. of CRC/person-years | 1,017/824,989 | 2,386/2,482,769 | 687/828,049 |
| Absolute risk | 1.3% | 1.6% | 0.9% |
| HR (95% CI) | 1.00 (ref) | 0.78 (0.73–0.84) | 0.67 (0.61–0.74) | <0.001 |

CRC, colorectal cancer; HR, hazard ratio; CI, confidence interval.

*aCox proportional hazards regression adjusted for age, sex, education, Townsend deprivation index, first 10 genetic principal components, and healthy lifestyle scores. p-value for trend was modeling the lifestyle categories as a continuous variable.
absolute CRC risk according to genetics, diet, BMI, smoking, alcohol consumption, exercise, and colonoscopy history, and found that the OR for high genetic risk was about 2.20 vs. that for the low genetic risk, and the OR for a favorable lifestyle was about 0.50 vs. that for an unfavorable lifestyle (3). Our research included six dimensions of 16 lifestyle factors and provided quantitative results to complement the joint effects of genetic risk and lifestyle factors on CRC. These results revealed a strong association of genetic and lifestyle factors with the risk of CRC. Our study supports the long-held view that genetic variants identifiable at birth change the risk of CRC (42–44), which is beneficial for the primary prevention of CRC.

Numerous biological mechanisms have been proposed to explain the association of genetics and lifestyle with the risk of CRC. Insufficient exercise affects the body’s immune system and depresses immune function in CRC, while nicotine may partially promote colorectal tumor growth and angiogenesis (45). Excess drinking causes acetaldehyde to accumulate in the colorectum, which may cause DNA damage (46). Inadequate sleep may affect

### Table 4 Risk of CRC according to lifestyle category within each PRS category.

| Lifestyle category | High genetic risk | Intermediate genetic risk | Low genetic risk |
|--------------------|-------------------|--------------------------|-----------------|
|                    | Unfavorable       | Intermediate             | Favorable       |
|                    | (n = 19,043)      | (n = 41,249)             | (n = 17,781)    |
| No. of CRC cases/person-years | 305/199,687 | 526/436,389 | 186/188,913 |
| Absolute risk      | 1.6%              | 1.3%                     | 1.0%            |
| HR (95% CI)*       | 1.00              | (0.72–0.96)              | (0.60–0.87)     |
| p-value            | 0.012             | <0.001                   | <0.001          |
| p-value for trend  | 0.002             | 0.001                    | 0.001           |

CRC, colorectal cancer; HR, hazard ratio; CI, confidence interval.
*Cox proportional hazards regression adjusted for age, sex, education, Townsend deprivation index, and first 10 genetic principal components.

---

### Table 4 Risk of CRC according to lifestyle category within each PRS category.

| Subgroup         | Total No. of participants | No. of cases of CRC/person-years | HR (95% CI) | p-value |
|------------------|---------------------------|----------------------------------|-------------|---------|
| High genetic risk|                           |                                  |             |         |
| Unfavorable LF   | 19043                     | 305/199,687                      | 1.00(ref)   | 0.13    |
| Intermediate LF  | 41249                     | 526/436,389                      | 0.84(0.73–0.96) | 0.001  |
| Favorable LF     | 17781                     | 186/188,913                      | 0.73(0.60–0.87) |         |
| Intermediate genetic risk | 57508 | 785/605,264 | 0.86(0.75–0.98) | 0.020  |
| Unfavorable LF   | 123,359                   | 1188/1309,033                    | 0.63(0.56–0.72) | <0.001  |
| Favorable LF     | 53356                     | 413/568,462                      | 0.54(0.47–0.63) | <0.001  |
| Low genetic risk |                           |                                  |             |         |
| Unfavorable LF   | 18866                     | 209/198,670                      | 0.69(0.58–0.82) | <0.001  |
| Intermediate LF  | 41201                     | 363/437,356                      | 0.57(0.49–0.66) | <0.001  |
| Favorable LF     | 18002                     | 115/192,042                      | 0.44(0.36–0.55) | <0.001  |
which are general rather than specific for certain risks. Second, several participants were excluded because of missing values, which may have significantly reduced the data. Third, the lifestyle factors that we constructed did not include all possible lifestyle factors such as aspirin medication history, family history of CRC, and other possible influencing factors. Incorporating them into the model may help improve the accuracy of CRC risk assessment. Finally, this study mainly focused on participants from a white ethnic background. Future studies should evaluate the generalizability of these research results to other populations.

Conclusions

In conclusion, our findings validate that low genetic risk and a favorable lifestyle are significantly associated with a decreased CRC risk. Additionally, we found that a favorable lifestyle was associated with a lower CRC risk in any genetic background, indicating the potential of modifiable lifestyle factors in CRC prevention.

Data availability statement

Publicly available datasets were analyzed in this study. The data can be found here: The FinnGen cohort Genome-wide association study (GWAS) summary data are openly available from the website https://finngen.gitbook.io/documentation/ (R5). The UK Biobank datasets are openly available by submitting a data request proposal from https://www.ukbiobank.ac.uk/. We are able to access the UK Biobank database through the Access Management System (AMS). The application number is 78563.

Author contributions

EW performed the statistical analysis and wrote the manuscript. J-TN designed the study. XC, Z-HZ, and H-QX were responsible for technical support. TX and LT revised the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This research was funded by the General Projects of National Natural Science Foundation of China (81973635) (to TX) and the Start-up Grant of HZNU (4125CS021720421) (to LT). The funding sources had no role in the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the article for publication.

Acknowledgments

We thank the participants and staff of the UK Biobank for their dedication and contribution to the research.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The reviewer XC declared a shared parent affiliation with the author JN to the handling editor at the time of review.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.894086/full#supplementary-material

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin (2018) 68(6):394-424. doi:10.3322/cacac.21492
2. Huyghe JR, Bien SA, Harrison TA, Kang HM, Chen S, Schmit SL, et al. Discovery of common and rare genetic risk variants for colorectal cancer. Nat Genet (2019) 51(1):76-87. doi: 10.1038/s41467-019-09775-w
3. Carr PR, Wegl K, Edeleman D, Jansen L, Chang-Claude J, Brenner H, et al. Estimation of absolute risk of colorectal cancer based on healthy lifestyle, genetic risk, and colonoscopy status in a population-based study - ScienceDirect. Gastroenterology (2020) 159(1):129-38. doi: 10.1053/j.gastro.2020.03.016
4. Fujita M, Liu X, Iwasa Y, Terao C, Mizukami K, Kawakami E, et al. Population-based screening for hereditary colorectal cancer variants in Japan. Clin Gastroenterol Hepatol (2022) 20(9):2132-2141.e9. doi: 10.1016/j.cgh.2020.12.007
5. Law PJ, Timofoeva M, Fernandez-Rozadilla C, Broderick P, Thibodeau SN. Association analyses identify 31 new risk loci for colorectal cancer susceptibility. Nat Commun (2019) 10(1):2154. doi: 10.1038/s41467-019-09775-w
risk score analyses. Nat Protoc doi: 10.1038/nature08185

Visscher PM, O'Donovan MC, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. PLoS Genetics (2012) 8(1):e1002446. doi: 10.1371/journal.pgen.1002446

Jeon J, Du M, Schoen RE, Hoffmeister M, et al. A tutorial on conducting genome-wide association studies: Quality control and interim analyses. J Healthc Inform Res (2012) 6(4):211-20. doi: 10.1136/jhir.6.4.211

Bur nett-Hartman AN, Newcomb PA, Peters U. Challenges with colorectal cancer family history assessment-motivation to translate polygenic risk scores into practice. Gastroenterology (2019) 158(2):433–5. doi: 10.1053/j.gastro.2019.10.030

Tanaman K, van den Berg L, Valimäki N, Aavikko M, Nissinen E, Hveem K, et al. Genome-wide association study and meta-analysis in northern European populations replicate multiple colorectal cancer risk loci. Int J Cancer (2018) 142(3):540–6. doi: 10.1002/ijc.31076

Rock CL, Thompson C, Gan sler T, Gapstur SM, McCullough ML, Patel AV, et al. American Cancer society guideline for diet and physical activity for cancer prevention. CA Cancer J Clin (2020) 70(4):245–71. doi: 10.3322/caac.21591

Zheng B, Yu C, Lv J, Gao Y, Bian Z, Zhou M, et al. Insomnia symptoms and risk of cardiovascular diseases among 0.5 million adults: A 10-year cohort. Neurology (2019) 93(23):e2110–20. doi: 10.1212/wnl.0000000000008581

Kripke DF, Simon RN, Garfinkel L, Hammond EC. Short and long sleep and sleeping pills. Is increased mortality associated? Arch Gen Psychiatry (1979) 36(1):103–16. doi: 10.1001/archpsyc.1979.01780010109014

Erren TL, Morfill RG, Reiter RJ, Gross V, Westermann IK. Sleep and cancer: Systematic review of experimental data and meta-analyses of cancer incidence among some 1,500,000 study individuals in 13 countries. Chronobiol Int (2016) 33(4):325–50. doi: 10.3109/07420528.2015.1144986

Zhang X, Giovannucci EL. Wu K, Ku X, Gao X, Jian Z, Zhou M, et al. Insomnia symptoms and risk of cardiovascular diseases among 0.5 million adults: A 10-year cohort. Neurology (2019) 93(23):e2110–20. doi: 10.1212/wnl.0000000000008581

Zhao H, Yin JY, Yang WS, Qin J, Li TT, Shi Y, et al. Sleep duration and cancer risk: a systematic review and meta-analysis of prospective studies. Asian Pac J Cancer Prev (2013) 14(12):7509–15. doi: 10.7314/apjcp.2013.14.12.7509

International Schizophrenia Consortium, Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature (2009) 460(7256):748–52. doi: 10.1038/nature08185

Choi SW, Mak TS, O'Reilly PF. Tutorial: a guide to performing polygenic risk score analyses. Nat Protoc (2020) 15(9):2759-72. doi: 10.1038/s41596-020-0353-1

Marees AT, de Kluiver H, Stringer S, Vorspan F, Currie E, Marie-Claire C, et al. A tutorial on conducting genome-wide association studies: Quality control and statistical analysis. Int J Methods Psychiatr Res (2018) 27(1):e1608. doi: 10.1002/imp.1608

Choi SW, O'Reilly PF. PRSice-2: Polygenic risk score software for biobank-scale data. GigaScience (2019) 8(7):giz082. doi: 10.1136/bmj.c5504

Euseden J, Lewis CM, O'Reilly PF. PRSice Polygenic risk score software. Bioinf (Oxford, England) (2015) 31(9):1466–8. doi: 10.1093/bioinformatics/btu848

Lin CL, Liu TC, Wang YN, Chung CH, Chien WC. The association between sleep disorders and the risk of colorectal cancer in patients. A population-based nested case-control study. In Vivo (2019) 33(2):573–9. doi: 10.21873/invivo.11513

Gu WJ, Pei YF, Zhang L, Haruki K, Ogino S, et al. Evaluating the utility of genomic risk scores in identifying high-risk individuals for eight common cancers. INCI Cancer Spects (2020) 4(3):pkaa021. doi: 10.1093/nicancer/pkaa021

Carr PR, Weigl K, Jansen L, Walter V, Erben V, Chang-Clau de J, et al. Healthy lifestyle factors associated with lower risk of colorectal cancer irrespective of genetic risk. Gastroenterology (2018) 155(6):1805–18. doi: 10.1053/j.gastro.2018.08.044

Aleksandrova K, Pischon T, Jenab M, Bueno-de-Mesquita HB, Fehl vor K, Norat T. Combined impact of healthy lifestyle factors on colorectal cancer: A large Chinese retrospective case-control study. PLoS One (2015) 10(12):e0143686. doi: 10.1371/journal.pone.0143686

Kirkegaard H, Johnsen NS, Christensen J, Frederiksen K, Overvad K, Tjønneland A. Association of adherence to lifestyle recommendations and risk of colorectal cancer: A Large Chinese retrospective case-control study. PLoS One (2015) 10(12):e0143686. doi: 10.1371/journal.pone.0143686

Choi J, Jia G, Wen W, Shu XO, Zheng W. Healthy lifestyle, genetic modifiers, and colorectal cancer risk: a prospective cohort study in the UK biobank. Am J Clin Nutr (2019) 111(4):810–20. doi: 10.1093/ajcn/nqaa404

Khera AV, Emdin CA, Drake I, Natarajan P, Bick AG, Cook NR, et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. N Engl J Med (2016) 375(24):2349–58. doi: 10.1056/NEJMc1606508

Chen X, Jansen L, Guo F, Hoffmeister M, Chang-Clau de J, Brena rr H. Smoking, genetic predisposition, and colorectal cancer risk: a prospective Danish cohort study. Br J Cancer (2011) 104(1):550–4. doi: 10.1038/bjc.2011.99

Bustoros M, Sklaventis-Pisotidis R, Park J, Redd R, Zhitomirsky B, Dunford AJ, et al. Genetic profiling of smoking multiple myeloma identifies patients at a high risk of disease progression. J Clin Oncol (2020) 38(21):2380–9. doi: 10.1200/JCO.20.00437

Khera AV, Emdin CA, Drake I, Natarajan P, Bick AG, Cook NR, et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. N Engl J Med (2016) 375(24):2349–58. doi: 10.1056/NEJMc1606508

Chen X, Jansen L, Guo F, Hoffmeister M, Chang-Clau de J, Brenner H. Smoking, genetic predisposition, and colorectal cancer risk. Clin Transl Gastroenterol (2021) 12(3):e00317. doi:10.14309/ctg.0000000000000317

Wong HP, Yu L, Lam EM, Tai EW, Wu KW, Cho CH. Nicotine promotes cell proliferation via alpha7-nicotinic acetylcholine receptor and catecholamine-synthesizing enzymes-mediated pathway in human colon adenocarcinoma HT-29 cells. Toxicol Appl Pharmacol (2007) 221(3):261–7. doi: 10.1016/j.taap.2007.04.002

Seitz HK, Stickel F. Molecular mechanisms of alcohol-mediated carcinogenesis. Nat Rev Cancer (2007) 7(8):599–612. doi: 10.1038/nrc2191

Savvidis C, Koutsilieris M. Circadian rhythm disruption in cancer biology. Mol Med (2012) 18:1249–60. doi: 10.2119/molmed.2012.00077

Zhang L, Shay JW. Multiple roles of APC and its therapeutic implications in colorectal cancer. J Natl Cancer Inst (2017) 109(8):dpw322. doi: 10.1093/jnci/djw332

Cicanis J, Tamosaitis L, Karederavice K, Tarvadya R, Stanuute G, Kalyan K, et al. KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma. Med Oncol (2017) 34(2):26. doi: 10.1007/s12032-016-0879-9